Primary objective:~To determine change of corrected QT interval (QTc) during intravenous argatroban infusion in patients undergoing percutaneous coronary intervention (PCI).~Secondary objectives:~Determination of the QTc interval after sufficient wash-out period by ECG-3 which needed to be performed > 8 but ≤ 28 hours after termination of prolonged argatroban infusion.~Investigation of dependence of QTc interval on gender and applied doses.~Determination of coagulation status during argatroban therapy.~Assessment of safety-related events within the scope of anticoagulation with argatroban, for example bleeding events or thromboembolic events.
To determine change of QTc interval during intravenous argatroban infusion in patients undergoing percutaneous coronary intervention (PCI)